There is also the latest progress in testing!, Is the nine valent HPV vaccine no longer difficult to obtain with just one shot? Multiple communities indicate availability of goods

With the improvement of individual self-protection awareness, more and more women are joining the ranks of receiving HPV vaccines. However, in the past few years, HPV vaccines have been in short supply due to limited production capacity, and the nine valent HPV vaccine has been in short supply for a long time. How is the supply situation this year?

Is the nine valent HPV vaccine no longer difficult to obtain with just one shot?

Multiple communities indicate availability of goods

On September 6th, the reporter called several HPV vaccination sites in Beijing, Shanghai, Guangzhou, Guangdong, Changsha, Hunan, and other places, and all replied that the nine valent HPV vaccine was ready for appointment.

"The difficulty of making an appointment for the nine valent HPV vaccine this year has been much better than last year. I have completed my second dose now, and all appointments are made through the official mini program in Beijing. However, it should be noted that the release time for each community service center is different, so it is important to consult in advance," Li Min from Chaoyang District, Beijing told reporters.

Several vaccination outpatient staff and vaccinators who provide appointment services for the nine valent HPV vaccine have told reporters that the difficulty of making appointments for the nine valent HPV vaccine has significantly decreased since the beginning of this year.

A staff member from the Heping Street Community Service Center in Chaoyang District, Beijing, told reporters, "It is indeed easy to schedule this year's nine valent HPV vaccine. Even if we cannot schedule it this week in our community, we will definitely be able to schedule it next week."

"The supply of imported nine valent vaccines in China has increased, so the public feels that the nine valent vaccines will be better contracted in the near future than before," said Qiao Youlin, a professor at the Cancer Hospital of the Chinese Academy of Medical Sciences and the School of Group Medicine and Public Health at Peking Union Medical College, in an interview with reporters. At present, the nine valent vaccines that can be administered are still developed by MSD, but domestic multi valent vaccines are also accelerating development. Nine valent, eleven valent, and even fourteen valent vaccines are all in clinical trials.

In fact, Merck increases the supply of the nine valent HPV vaccine every year. According to the financial report of Zhifei Biotechnology, the domestic agent of MSD, the annual batch issuance of the nine valent HPV vaccine reached 15.47232 million units in 2022, a year-on-year increase of 51.65%; From January to June 2023, the batch issuance of the nine valent HPV vaccine reached 14.6782 million units, a year-on-year increase of 57.85%.

The research on HPV vaccines by domestic pharmaceutical companies is also constantly advancing. According to a search by reporters, there are currently more than 10 domestic companies that have laid out HPV vaccines, including Xiamen Wantai Canghai, Ruike Biology, Kangle Weishi, Shanghai Zerun, Bowei Biology, Watson Biology, and Shenzhou Cell. Among them, nine valent HPV vaccines from Wantai Biology, Ruike Biology, Watson Biology, Kangle Weishi, and Shanghai Bowei have entered clinical phase III.

Expected to achieve HPV screening for urinary and cervical cancer in 2027

In addition, there have been recent developments in HPV detection.

On the 7th, # 27 is expected to achieve HPV screening for cervical cancer in urine, which has sparked discussions. According to the Qianjiang Evening News, the baseline data of PREVENT, the largest prospective registered clinical trial for cancer early screening in China, was recently released in Hangzhou. The data stated that China is expected to achieve HPV screening for cervical cancer in urine by 2027. Testers can cover 14 high-risk HPV virus screenings by sampling 20-30 milliliters of urine at home.

The trial was led by Peking University People's Hospital, in collaboration with six tertiary hospitals in Beijing, Zhejiang, Henan, Hunan, Sichuan, and other regions. A total of 16744 participants were included, and the results showed a total conformity rate of 97.42% between urine testing and cervical samples.

According to the recommendations on the WHO website for the prevention and treatment of cervical cancer, screening and vaccination with HPV vaccine are the most effective methods for preventing cervical cancer. However, vaccination with HPV vaccine cannot replace cervical cancer screening, and vaccination cannot prevent all HPV viruses.

Can HPV vaccines be paid with medical insurance?

According to regulations, non immunization vaccine fees that currently comply with the national medical insurance information business code management can be paid through medical insurance card swiping or personal medical insurance account. Non immunization planning vaccines, also known as "Class II vaccines", belong to vaccines that residents voluntarily vaccinate at their own expense, such as common HPV vaccines, hepatitis B vaccines, influenza vaccines, etc. However, it should be noted that payments can only be made through personal medical insurance accounts and cannot be made through pooling funds.

The immunization program vaccine refers to the vaccine that residents should receive according to government regulations, which is similar in concept to the previous type of vaccine and is borne by the government.

So, is it possible for non immune planning vaccines to be converted into immune planning vaccines? According to Tao Lina, former chief physician of the Immune Planning Department of the Shanghai Center for Disease Control and Prevention, it is not impossible for Class II to be converted to Class I, but there are also many obstacles. To transform, there must also be a sense of importance and urgency.

Regarding whether the HPV vaccine, which is of great concern to the public, can be included in the immunization plan, Tao Lina stated that the cervical cancer vaccine should achieve a vaccination rate of over 90% for women aged 9-14 by 2030, which to some extent means that it will be included in the immunization plan and become a free vaccine. At present, many regions have begun to promote free cervical cancer vaccination for eligible women.

Zhongxin Jingwei Comprehensive, including Zhongxin Jingwei, People's Daily Health Client, Qianjiang Evening News, etc